Ross Stuart Berkowitz, M.D.
This page shows the publications co-authored by Ross Berkowitz and Susana Campos.
Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.